JP2012527867A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012527867A5 JP2012527867A5 JP2011550339A JP2011550339A JP2012527867A5 JP 2012527867 A5 JP2012527867 A5 JP 2012527867A5 JP 2011550339 A JP2011550339 A JP 2011550339A JP 2011550339 A JP2011550339 A JP 2011550339A JP 2012527867 A5 JP2012527867 A5 JP 2012527867A5
- Authority
- JP
- Japan
- Prior art keywords
- peptide
- group
- amino acid
- apc
- ctl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims 28
- 150000001413 amino acids Chemical class 0.000 claims 13
- 229940024606 amino acid Drugs 0.000 claims 10
- 210000000612 antigen-presenting cell Anatomy 0.000 claims 10
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 claims 10
- 239000002157 polynucleotide Substances 0.000 claims 7
- 102000040430 polynucleotide Human genes 0.000 claims 7
- 108091033319 polynucleotide Proteins 0.000 claims 7
- 230000001939 inductive effect Effects 0.000 claims 5
- 238000000034 method Methods 0.000 claims 5
- 239000000427 antigen Substances 0.000 claims 4
- 108091007433 antigens Proteins 0.000 claims 4
- 102000036639 antigens Human genes 0.000 claims 4
- 210000001808 exosome Anatomy 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 102000004196 processed proteins & peptides Human genes 0.000 claims 4
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims 3
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims 3
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims 3
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 210000001744 T-lymphocyte Anatomy 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 3
- 238000000338 in vitro Methods 0.000 claims 3
- 229930182817 methionine Natural products 0.000 claims 3
- 239000000203 mixture Substances 0.000 claims 3
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims 2
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims 2
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims 2
- 239000004480 active ingredient Substances 0.000 claims 2
- 238000012258 culturing Methods 0.000 claims 2
- 239000013604 expression vector Substances 0.000 claims 2
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims 2
- 230000008685 targeting Effects 0.000 claims 2
- 125000001433 C-terminal amino-acid group Chemical group 0.000 claims 1
- 238000009007 Diagnostic Kit Methods 0.000 claims 1
- 108010074032 HLA-A2 Antigen Proteins 0.000 claims 1
- 102000025850 HLA-A2 Antigen Human genes 0.000 claims 1
- 108010013476 HLA-A24 Antigen Proteins 0.000 claims 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims 1
- -1 SEQ ID NO: 2 amino acid Chemical class 0.000 claims 1
- 108091008874 T cell receptors Proteins 0.000 claims 1
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 230000028993 immune response Effects 0.000 claims 1
- 239000004615 ingredient Substances 0.000 claims 1
- 229960000310 isoleucine Drugs 0.000 claims 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims 1
- 239000002773 nucleotide Substances 0.000 claims 1
- 125000003729 nucleotide group Chemical group 0.000 claims 1
- 229920001184 polypeptide Polymers 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 238000001356 surgical procedure Methods 0.000 claims 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims 1
- 239000004474 valine Substances 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US21713309P | 2009-05-26 | 2009-05-26 | |
| US61/217,133 | 2009-05-26 | ||
| PCT/JP2010/003488 WO2010137295A1 (en) | 2009-05-26 | 2010-05-25 | Cdc45l peptides and vaccines including the same |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012527867A JP2012527867A (ja) | 2012-11-12 |
| JP2012527867A5 true JP2012527867A5 (enExample) | 2013-07-11 |
| JP5903697B2 JP5903697B2 (ja) | 2016-04-20 |
Family
ID=43222423
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011550339A Active JP5903697B2 (ja) | 2009-05-26 | 2010-05-25 | Ｃｄｃ４５ｌペプチドおよびそれを含むワクチン |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US8586547B2 (enExample) |
| EP (4) | EP3556857B1 (enExample) |
| JP (1) | JP5903697B2 (enExample) |
| KR (1) | KR101765452B1 (enExample) |
| CN (3) | CN103694315B (enExample) |
| AU (1) | AU2010253356B2 (enExample) |
| BR (1) | BRPI1010666B1 (enExample) |
| CA (3) | CA2762934C (enExample) |
| DK (3) | DK2435567T3 (enExample) |
| ES (3) | ES2631952T3 (enExample) |
| IL (1) | IL216211A (enExample) |
| MX (1) | MX2011012619A (enExample) |
| RU (1) | RU2562160C2 (enExample) |
| SG (1) | SG176058A1 (enExample) |
| TW (1) | TWI507204B (enExample) |
| WO (1) | WO2010137295A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2633503C2 (ru) | 2011-10-28 | 2017-10-12 | Онкотерапи Сайенс, Инк. | Пептиды торк и содержащие их вакцины |
| EP3202783A1 (en) | 2016-02-02 | 2017-08-09 | Ecole Polytechnique Fédérale de Lausanne (EPFL) | Engineered antigen presenting cells and uses thereof |
| CN110191703B (zh) | 2017-01-25 | 2022-04-08 | 奥塞免疫疗法公司 | 用于肽递送的稳定乳液的制造方法 |
| KR102742220B1 (ko) | 2017-09-19 | 2024-12-17 | 더 유니버시티 오브 브리티쉬 콜롬비아 | 항-hla-a2 항체 및 그 사용 방법 |
| US11814432B2 (en) | 2017-09-20 | 2023-11-14 | The University Of British Columbia | Anti-HLA-A2 antibodies, related chimeric antigen receptors, and uses thereof |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4722848A (en) | 1982-12-08 | 1988-02-02 | Health Research, Incorporated | Method for immunizing animals with synthetically modified vaccinia virus |
| EP0239102A3 (en) | 1986-03-28 | 1989-07-12 | Tsuji, Kimiyoshi | Process for the formation of human-human hybridoma |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
| US5108921A (en) | 1989-04-03 | 1992-04-28 | Purdue Research Foundation | Method for enhanced transmembrane transport of exogenous molecules |
| US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| ES2246502T3 (es) | 1990-08-29 | 2006-02-16 | Genpharm International, Inc. | Animales no humanos transgenicos capaces de producir anticuerpos heterologos. |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5679647A (en) | 1993-08-26 | 1997-10-21 | The Regents Of The University Of California | Methods and devices for immunizing a host against tumor-associated antigens through administration of naked polynucleotides which encode tumor-associated antigenic peptides |
| US5804566A (en) | 1993-08-26 | 1998-09-08 | The Regents Of The University Of California | Methods and devices for immunizing a host through administration of naked polynucleotides with encode allergenic peptides |
| US5739118A (en) | 1994-04-01 | 1998-04-14 | Apollon, Inc. | Compositions and methods for delivery of genetic material |
| US5736524A (en) | 1994-11-14 | 1998-04-07 | Merck & Co.,. Inc. | Polynucleotide tuberculosis vaccine |
| US5922687A (en) | 1995-05-04 | 1999-07-13 | Board Of Trustees Of The Leland Stanford Junior University | Intracellular delivery of nucleic acids using pressure |
| EP0841945B1 (en) | 1995-08-03 | 2006-03-08 | Rijksuniversiteit te Leiden | Cell derived antigen presenting vesicles |
| US5853719A (en) | 1996-04-30 | 1998-12-29 | Duke University | Methods for treating cancers and pathogen infections using antigen-presenting cells loaded with RNA |
| JP2000516090A (ja) | 1996-07-26 | 2000-12-05 | スローン―ケッタリング インスティチュート フォー キャンサー リサーチ | 遺伝子的免疫化のための方法と試薬 |
| US20020132252A1 (en) * | 1997-06-16 | 2002-09-19 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| FR2766205B1 (fr) | 1997-07-16 | 2002-08-30 | Inst Nat Sante Rech Med | Nouveau procede de sensibilisation de cellules presentatrices d'antigene et nouveaux moyens pour la mise en oeuvre du procede |
| AU749544B2 (en) | 1998-06-25 | 2002-06-27 | Dainippon Sumitomo Pharma Co., Ltd. | Tumor antigen peptides originating in cyclophilin B |
| EP2336167B1 (en) | 2001-03-14 | 2019-05-29 | Dako Denmark A/S | MHC molecule constructs and their uses for diagnosis and therapy |
| CA2399569A1 (en) | 2001-09-25 | 2003-03-25 | Yusuke Nakamura | Diagnostic markers and drug targets for treatment of cancer |
| GB2392158B (en) | 2002-08-21 | 2005-02-16 | Proimmune Ltd | Chimeric MHC protein and oligomer thereof |
| EP2267023B1 (en) * | 2002-09-12 | 2015-02-11 | Oncotherapy Science, Inc. | KDR peptides and vaccines comprising the same |
| WO2006031221A1 (en) | 2004-09-13 | 2006-03-23 | Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Compositions comprising t cell receptors and methods of use thereof |
| JP4370409B2 (ja) | 2005-06-22 | 2009-11-25 | 国立大学法人東北大学 | がんの予後予測方法 |
| EP1907582B1 (en) * | 2005-07-27 | 2012-01-04 | Oncotherapy Science, Inc. | Ect2 as a therapeutic target for esophageal cancer |
| EP2305811A1 (en) | 2005-07-27 | 2011-04-06 | Oncotherapy Science, Inc. | Method of diagnosing smal cell lung cancer |
| CN101287831B (zh) | 2005-09-13 | 2013-05-15 | 国立大学法人三重大学 | T细胞受体和编码该受体的核酸 |
| RU2451521C2 (ru) * | 2006-06-16 | 2012-05-27 | Онкотерапи Сайенс, Инк. | Sparc-производные антигенные пептиды отторжения опухоли и лекарственные средства, содержащие их |
| US8470534B2 (en) | 2006-12-01 | 2013-06-25 | Erik S. Knudsen | Methods of predicting resistance or sensitivity to therapies for cancer |
| TWI441648B (zh) * | 2007-01-03 | 2014-06-21 | Oncotherapy Science Inc | Ｆｏｘｐ３胜肽疫苗 |
-
2010
- 2010-05-21 TW TW099116260A patent/TWI507204B/zh not_active IP Right Cessation
- 2010-05-25 RU RU2011152975/10A patent/RU2562160C2/ru active
- 2010-05-25 JP JP2011550339A patent/JP5903697B2/ja active Active
- 2010-05-25 EP EP19175920.8A patent/EP3556857B1/en active Active
- 2010-05-25 ES ES10780256.3T patent/ES2631952T3/es active Active
- 2010-05-25 AU AU2010253356A patent/AU2010253356B2/en not_active Ceased
- 2010-05-25 KR KR1020117030872A patent/KR101765452B1/ko not_active Expired - Fee Related
- 2010-05-25 SG SG2011083813A patent/SG176058A1/en unknown
- 2010-05-25 CN CN201310610796.8A patent/CN103694315B/zh not_active Expired - Fee Related
- 2010-05-25 EP EP17163532.9A patent/EP3208334B1/en active Active
- 2010-05-25 CN CN201080033325XA patent/CN102459589B/zh not_active Expired - Fee Related
- 2010-05-25 DK DK10780256.3T patent/DK2435567T3/en active
- 2010-05-25 WO PCT/JP2010/003488 patent/WO2010137295A1/en not_active Ceased
- 2010-05-25 EP EP10780256.3A patent/EP2435567B1/en not_active Not-in-force
- 2010-05-25 CA CA2762934A patent/CA2762934C/en active Active
- 2010-05-25 EP EP21160385.7A patent/EP3868778A3/en not_active Withdrawn
- 2010-05-25 MX MX2011012619A patent/MX2011012619A/es active IP Right Grant
- 2010-05-25 CN CN201510386650.9A patent/CN105153279B/zh not_active Expired - Fee Related
- 2010-05-25 ES ES17163532T patent/ES2746334T3/es active Active
- 2010-05-25 ES ES19175920T patent/ES2875950T3/es active Active
- 2010-05-25 BR BRPI1010666-9A patent/BRPI1010666B1/pt not_active IP Right Cessation
- 2010-05-25 DK DK17163532.9T patent/DK3208334T3/da active
- 2010-05-25 CA CA3167451A patent/CA3167451A1/en active Pending
- 2010-05-25 CA CA3011607A patent/CA3011607C/en active Active
- 2010-05-25 US US13/321,812 patent/US8586547B2/en not_active Expired - Fee Related
- 2010-05-25 DK DK19175920.8T patent/DK3556857T3/da active
-
2011
- 2011-11-08 IL IL216211A patent/IL216211A/en active IP Right Grant